Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IPRHW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
RC58-ADC-1
|
|||||
| Synonyms |
RC58-ADC 1; RC58-ADC1
Click to Show/Hide
|
|||||
| Organization |
RemeGen Co., Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
B-cell lymphoma [ICD11:2A86]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.8
|
|||||
| Structure |
|
|||||
| Antibody Name |
RC58
|
Antibody Info | ||||
| Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
| Payload Name |
Dumycin-7
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Bis-bromine linker-PEG4-Asn-Ala-ethylenediamine
|
Linker Info | ||||
| Conjugate Type |
Reduction of inter-molecule chain disulfide bonds can produce free sulfhydryl groups which support the conjunction of antibody and drug at specific cysteine residues via maleimide-containing linkers.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.